Investors were alerted on August 21, 2026, when Richard Close of Canaccord Genuity adjusted his rating for Health Catalyst, Inc. (HCAT) to ‘Hold.’ The firm presented a price target of $1.80, a modest upside from its current price of $1.63. As the healthcare analytics company navigates turbulent market conditions, this rating shift serves as a signal to investors weighing their options in this volatile sector.
Recent Price Action
Health Catalyst has witnessed a noteworthy decline in its stock price, dropping approximately 3.37% in the last trading session, equating to a decrease of $0.055. Currently priced at $1.63, HCAT has fallen dramatically from its 52-week high of $4.79, representing a staggering decline of 65.62%. Over the past week, the stock’s trading behavior has reflected higher volatility, with an average weekly fluctuation of 5.52%. Trading volume stood at 369,673, significantly lower than its average volume of 1.33 million shares, indicating a potential lack of investor confidence amid market fluctuations. With a market capitalization of $116.38 million and a beta of 1.557, Health Catalyst exhibits a higher level of volatility compared to the broader market.
Historical Performance
The performance of HCAT over various time frames illustrates increasing investor hesitance. Over the past 30 days, the stock has dropped 7.53%, indicating an ongoing lack of momentum. A more alarming quarterly performance reflects a staggering decline of 27.54%, while a year-long performance reveals a staggering fall of nearly 60%. The stock’s average trading volume over the last three months has decreased to approximately 1.65 million, indicating diminished interest from buyers amid broader market stresses. This trend raises questions about the stock’s future, especially within a sector that continues to grapple with fluctuating investor sentiment.
Earnings Analysis
On the earnings front, Health Catalyst recently reported stronger-than-anticipated results. For the most recent quarter, the company’s earnings per share (EPS) came in at $0.04, exceeding analyst expectations of $0.0299—a surprising 33.87% beat. This improvement is worth noting as it follows a previous performance where the company delivered an EPS of $0.02, which was also significantly higher than the initial estimate of $0.01. Such marked performance indicates Health Catalyst’s ability to navigate challenges effectively and could reflect an evolving operational resilience.
Consensus Ratings
The consensus surrounding HCAT is overwhelmingly cautious. According to the latest ratings, there are three total ratings from analysts, comprising one ‘Buy’ and two ‘Hold’ recommendations, with no ‘Sell’ ratings reported. The average price target reflects a slight upside potential with a consensus average of $2.18, while the high and low price targets sit at $3.00 and $1.75, respectively. Canaccord Genuity’s recent designation of ‘Hold’ suggests a more tempered outlook, advising investors to consider potential risks and endurance before committing new capital.
Stocks Telegraph Grading
The Stocks Telegraph Grade for Health Catalyst, Inc. currently stands at 36, summarizing the company’s overall health and investment profile based on financial and market analyses. This relatively low score underscores significant challenges the company faces and suggests that while there are some strengths, the potential for rapid recovery may be limited.
Conclusion
For investors considering Health Catalyst, this stock may align best with those possessing a high tolerance for risk and seeking a value play in the healthcare analytics sector. While the company has shown promise with positive earnings surprises, the persistent declines raise concerns that may deter more risk-averse investors. As market conditions remain fluid, HCAT warrants close observation, particularly regarding any changes in analyst sentiment or significant shifts in financial performance. Investors should weigh the risks of continued volatility against the potential for recovery to establish an informed stance on this under-pressure stock.